SLC22A25 is an organic anion transporter belonging to the SLC22 family of transmembrane proteins. Functionally, it is classified within the OATS4 subgroup, which specializes in transporting conjugated sex hormones, particularly etiocholanolone glucuronide 1. Like other SLC22 transporters, SLC22A25 is predominantly expressed in kidneys and liver, where it mediates the uptake and excretion of endogenous metabolites and xenobiotics 2. The transporter operates as part of an integrated SLC22 network that regulates multiple metabolites involved in organ crosstalk and inter-organismal communication 1. Clinically, SLC22A25 has emerged as a novel disease susceptibility locus for atrial fibrillation. A genetic variant (rs11231397, R300T) in SLC22A25 was significantly associated with atrial fibrillation risk in Japanese populations, with the minor C allele conferring increased susceptibility (odds ratio, 1.77; P=3.71×10⁻⁵) 3. Additionally, SNPs in SLC22A25 were associated with vulnerable plaque morphology in coronary atherosclerosis 4, suggesting broader cardiovascular implications. These genetic associations indicate that SLC22A25 variants may influence disease risk through altered transporter function, though the precise mechanistic link between conjugated steroid hormone transport and arrhythmia susceptibility requires further investigation.